Shin Nippon Biomedical Laboratories (FRA:YB3) ROCE %: 19.90% (As of Mar. 2026)


FRA:YB3 Shin Nippon Biomedical Laboratories Ltd FRA:YB3
74 GF Score
Price €6.00
GF Value €9.47
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories ROCE %?

Shin Nippon Biomedical Laboratories FRA:YB3 +1.69% 74 ROCE % is 19.90% as of Mar. 2026. GuruFocus rates FRA:YB3 with a GF Score™ of 74/100 and a GF Value™ of €9.47. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shin Nippon Biomedical Laboratories's annualized ROCE % for the quarter that ended in Mar. 2026 was 19.90%.

Shin Nippon Biomedical Laboratories  (FRA:YB3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shin Nippon Biomedical Laboratories ROCE % Related Terms

Shin Nippon Biomedical Laboratories ROCE % Historical Data

* Premium members only.

The historical data trend for Shin Nippon Biomedical Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shin Nippon Biomedical Laboratories ROCE % Chart

Shin Nippon Biomedical Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.44 24.39 15.14 10.78 9.50

Shin Nippon Biomedical Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.23 2.48 6.73 8.37 19.90
FRA:YB3
74GF Score
Shin Nippon Biomedical Laboratories Ltd FRA:YB3
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shin Nippon Biomedical Laboratories ROCE % Calculation

Shin Nippon Biomedical Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=35.654/( ( (573.505 - 181.554) + (572.671 - 214.367) )/ 2 )
=35.654/( (391.951+358.304)/ 2 )
=35.654/375.1275
=9.50 %

Shin Nippon Biomedical Laboratories's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=78.196/( ( (619.382 - 191.6) + (572.671 - 214.367) )/ 2 )
=78.196/( ( 427.782 + 358.304 )/ 2 )
=78.196/393.043
=19.90 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 19.90% mean?
Shin Nippon Biomedical Laboratories (FRA:YB3) has a ROCE % of 19.90% as of Mar. 2026.
Is Shin Nippon Biomedical Laboratories' ROCE % too high?
Shin Nippon Biomedical Laboratories' current ROCE % is 19.90%. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' ROCE % compare to TMO and DHR?
Shin Nippon Biomedical Laboratories' ROCE % of 19.90% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Shin Nippon Biomedical Laboratories's current ROCE % is 19.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (FRA:YB3) has a current ROCE % of 19.90%. The stock's GF Value™ is €9.47, compared to a current price of €6.00 — trading 36.6% below its estimated fair value. The current ROCE % is 19.90%. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (FRA:YB3), the current ROCE % is 19.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shin Nippon Biomedical Laboratories (FRA:YB3) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of €6.00 is trading 36.6% below its estimated GF Value™ of €9.47.

Key valuation signals for FRA:YB3:

  • ROCE %: 19.90%
  • GF Value™: €9.47 vs. price of €6.00 (36.6% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:YB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score

Get the complete analysis for FRA:YB3

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€9.47
GF Value